A natural protein may protect the GI tract from infection

2026-04-21 · Source: MIT Technology Review · Field: Science & Research — Life Sciences & Biology, Health & Medical Research · Depth: Intermediate, quick

Summary

MIT chemistry professor Laura Kiessling's team discovered that intelectin-2, a natural protein found in mucosal surfaces, provides dual protection for the gastrointestinal (GI) tract. Published on April 21, 2026, their research indicates that intelectin-2 both fortifies the mucosal barrier and offers broad-spectrum antimicrobial defense. The protein binds to galactose on bacterial membranes, trapping and disrupting pathogens like Staphylococcus aureus and Klebsiella pneumoniae, leading to their disintegration. Concurrently, it strengthens the intestinal lining by binding to galactose in mucins, which are components of mucus. This dual mechanism suggests intelectin-2 could be a therapeutic agent for inflammatory bowel disease and a novel antimicrobial against antibiotic-resistant pathogens.

Key takeaway

For AI scientists developing novel antimicrobial strategies, this research highlights intelectin-2 as a promising natural protein that both strengthens mucosal barriers and directly neutralizes antibiotic-resistant bacteria. You should consider exploring human lectins as a new class of therapeutic agents, leveraging the body's innate immune defenses to combat antimicrobial resistance and inflammatory bowel disease.

Key insights

Intelectin-2 offers dual GI tract protection by stabilizing mucus and directly neutralizing bacteria.

Principles

• Natural proteins can offer broad-spectrum antimicrobial defense.
• Innate immune defenses can be harnessed for new treatments.

Method

Intelectin-2 binds to galactose on bacterial membranes, trapping and disrupting them, while also binding to mucin galactose to stabilize the mucus layer.

In practice

• Investigate intelectin-2 as an antimicrobial agent.
• Explore intelectin-2 for inflammatory bowel disease treatment.

Topics

• Intelectin-2
• Mucosal Barrier
• Antimicrobial Resistance
• Inflammatory Bowel Disease
• GI Tract Infection

Best for: AI Scientist, Research Scientist, Domain Expert

Related on AIssential

• The scientist using AI to hunt for antibiotics just about everywhere — AI-driven peptide discovery from diverse biological sources offers a novel approach to combat antimicrobial resistance.
• Building the Backbone of Metabolic Health: Our Investment in Nourish — Nourish's success demonstrates how technology and operational innovation can bridge critical gaps in underutilized healthcare benefits.
• AgForce Enables Antigen-conditioned Generative Antibody Design — Existing antibody design models fail to condition on antigen, suffering from antigen blindness and vocabulary collapse due to cross-entropy loss.
• Using AI to outsmart drug-resistant bacteria — AI tools significantly accelerate antibiotic discovery by identifying non-intuitive biological patterns and generating novel therapeutic ideas.
• Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity — A health awakening is driving demand for peptides and advanced bio-interventions, emphasizing individual responsibility and future bio-communication.
• The hunt for the next antibiotics — Antimicrobial resistance threatens global health, necessitating urgent, diverse research into new antibiotics and resistance mitigation.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by MIT Technology Review.